{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:10:31Z","timestamp":1768878631965,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,10,29]],"date-time":"2009-10-29T00:00:00Z","timestamp":1256774400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1208\/s12249-009-9321-3","type":"journal-article","created":{"date-parts":[[2009,10,28]],"date-time":"2009-10-28T12:12:52Z","timestamp":1256731972000},"source":"Crossref","is-referenced-by-count":16,"title":["Physico-Chemical Characterization and In Vitro Dissolution Assessment of Clonazepam\u2014Cyclodextrins Inclusion Compounds"],"prefix":"10.1208","volume":"10","author":[{"given":"Rakesh","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirav","family":"Purohit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,10,29]]},"reference":[{"issue":"3\u20134","key":"9321_CR1","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0014-2999(83)90494-6","volume":"89","author":"JH Skerritt","year":"1983","unstructured":"Skerritt JH, Johnston GA. Enhancement of GABA binding by benzodiazepines and related anxiolytics. Eur J Pharmacol. 1983;89(3\u20134):193\u20138.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"9321_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/0014-2999(87)90617-0","volume":"135","author":"PF Lehoullier","year":"1987","unstructured":"Lehoullier PF, Ticku MK. Benzodiazepine and beta-carboline modulation of GABA-stimulated 36Cl-influx in cultured spinal cord neurons. Eur J Pharmacol. 1987;135(2):235\u20138.","journal-title":"Eur J Pharmacol"},{"key":"9321_CR3","first-page":"135","volume-title":"Pharmaceutics: the science of dosage from design","author":"S Proudfoot","year":"1991","unstructured":"Proudfoot S. Factors affecting bioavailability: factors influencing drug absorption from the gastrointestinal tract. In: Aulton ME, editor. Pharmaceutics: the science of dosage from design. Edinburgh: Churchill Livingstone; 1991. p. 135\u201373."},{"key":"9321_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0378-5173(86)90201-2","volume":"29","author":"J Pitha","year":"1986","unstructured":"Pitha J, Milecki J, Fales H, Pannell L, Uekama K. Hydroxypropyl-\u03b2-cyclodextrin: preparation and characterization; effects on solubility of drugs. Int J Pharm. 1986;29:73\u201382.","journal-title":"Int J Pharm"},{"key":"9321_CR5","unstructured":"Duch\u00eane D. Cyclodextrins and their industrial uses. Editions de Sant\u00e9 Paris, 1987; SS. 447\u2013460."},{"key":"9321_CR6","first-page":"73","volume":"58","author":"S Baboota","year":"2003","unstructured":"Baboota S, Agarwal SP. Rofecoxib complexation with \u03b2-cyclodextrin: influence on the anti-inflammatory and ulcerogenic activity. Die Pharmazie. 2003;58:73\u20134.","journal-title":"Die Pharmazie"},{"key":"9321_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0928-0987(01)00208-1","volume":"15","author":"CM Fernandes","year":"2002","unstructured":"Fernandes CM, Teresa VM, Veiga FJ. Physicochemical characterization and in vitro dissolution behavior of nicardipine-cyclodextrins inclusion compounds. Eur J Pharm Sci. 2002;15:79\u201388.","journal-title":"Eur J Pharm Sci"},{"key":"9321_CR8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0168-3659(02)00171-2","volume":"82","author":"M Kamada","year":"2002","unstructured":"Kamada M, Hirayama F, Udo K, Yano H, Arima H, Uekama K. Cyclodextrin conjugate-based controlled release system: repeated- and prolonged-releases of ketoprofen after oral administration in rats. J Control Release. 2002;82:407\u201316.","journal-title":"J Control Release"},{"key":"9321_CR9","doi-asserted-by":"crossref","unstructured":"Mukne AP, Nagarsenker MS. Triamterene-\u03b2-cyclodextrin systems: preparation, characterization and in vivo evaluation. AAPS PharmSci Tech. 2004;5:article 19.","DOI":"10.1208\/pt050119"},{"key":"9321_CR10","first-page":"1","volume":"3","author":"K Uekama","year":"1987","unstructured":"Uekama K, Otagiri M. Cyclodextrins in drug carrier systems. Crit Rev Ther Drug Carrier Syst. 1987;3:1\u201340.","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"9321_CR11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/med.2610140304","volume":"14","author":"J Szejtli","year":"1994","unstructured":"Szejtli J. Medicinal applications of cyclodextrins. Med Res Rev. 1994;14:353\u201386.","journal-title":"Med Res Rev"},{"key":"9321_CR12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.cplett.2005.01.103","volume":"405","author":"W Xianhong","year":"2005","unstructured":"Xianhong W, Ziyang L, Tianqiang Z. Mass spectrometry and molecular modeling studies on the inclusion complexes between \u03b1 \u03b2-cyclodextrins and simvastatin. Chem Phys Lett. 2005;405:114\u20137.","journal-title":"Chem Phys Lett"},{"key":"9321_CR13","doi-asserted-by":"publisher","first-page":"E83","DOI":"10.1208\/pt060114","volume":"6","author":"S Baboota","year":"2005","unstructured":"Baboota S, Dhaliwal M, Kohli K. Physicochemical characterization, in vitro dissolution behavior, and pharmacodynamic studies of rofecoxib-cyclodextrin inclusion compounds. AAPS PharmSciTech. 2005;6:E83\u201390.","journal-title":"AAPS PharmSciTech"},{"key":"9321_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1081\/PDT-100002612","volume":"6","author":"MK Ghorab","year":"2001","unstructured":"Ghorab MK, Adeyeye MC. Elucidation of solution state complexation in wet-granulated oven-dried ibuprofen and \u03b2-cyclodextrin: FT-IR and 1H-NMR studies. Pharm Dev Technol. 2001;6:315\u201324.","journal-title":"Pharm Dev Technol"},{"key":"9321_CR15","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1248\/cpb.49.1251","volume":"49","author":"FJ Veiga","year":"2001","unstructured":"Veiga FJ, Fernandes C, Carvalho RA, Geraldes CF. Molecular modeling and 1H-NMR: ultimate tools for the investigation of tolbutamide: \u03b2-cyclodextrin and tolbutamide: hydroxypropyl-\u03b2-cyclodextrin complexes. Chem Pharm Bull. 2001;49:1251\u20136.","journal-title":"Chem Pharm Bull"},{"key":"9321_CR16","doi-asserted-by":"publisher","first-page":"E45","DOI":"10.1208\/pt040345","volume":"4","author":"GS Tirucherai","year":"2003","unstructured":"Tirucherai GS, Mitra AK. Effect of hydroxypropyl beta cyclodextrin complexation on aqueous solubility, stability, and corneal permeation of acyl ester prodrugs of ganciclovir. AAPS PharmSciTech. 2003;4:E45.","journal-title":"AAPS PharmSciTech"},{"key":"9321_CR17","doi-asserted-by":"publisher","first-page":"E2","DOI":"10.1208\/pt040102","volume":"4","author":"BN Nalluri","year":"2003","unstructured":"Nalluri BN, Chowdary KPR, Murthy KVR, Hayman AR, Becket G. Physicochemical characterization and dissolution properties of nimesulide-cyclodextrin binary systems. AAPS Pharm Sci Tech. 2003;4:E2.","journal-title":"AAPS Pharm Sci Tech"},{"key":"9321_CR18","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1002\/jps.10126","volume":"91","author":"J Peeters","year":"2002","unstructured":"Peeters J, Neeskens P, Tollenaere JP, Van Remoortere P, Brewster ME. Characterization of the interaction of 2-hydroxypropyl-betacyclodextrin with itraconazole at pH 2, 4, and 7. J Pharm Sci. 2002;91:1414\u201322.","journal-title":"J Pharm Sci"},{"key":"9321_CR19","first-page":"64","volume":"20","author":"JW Moore","year":"1996","unstructured":"Moore JW, Flanner H. Mathematical comparison of dissolution profiles. Pharm Tech. 1996;20:64\u201374.","journal-title":"Pharm Tech"},{"key":"9321_CR20","unstructured":"Guidance for Industry SUPAC-MR: modified release solid oral dosage forms scale-up and postapproval changes: chemistry, manufacturing, and controls; in vitro dissolution testing and in vivo bioequivalence documentation. US Food and Drug Administration, Rockville, MD, USA, 1997. www.fda.gov\/cder\/guidance\/index.html ."},{"key":"9321_CR21","unstructured":"Human Medicines Evaluation Unit, EMEA. Notes for Guidance on Quality of Modified-Release Products; A Oral Dosage Forms; B Transdermal Dosage Forms, Section\u00a01 (Quality) 1999."},{"key":"9321_CR22","first-page":"229","volume-title":"Oral drug absorption prediction and assessment","author":"C Reppas","year":"2000","unstructured":"Reppas C, Nicolaides E. Analysis of drug dissolution data. In: Dressman JB, Lennern\u00e4s H, editors. Oral drug absorption prediction and assessment. New York: Marcel Dekker; 2000. p. 229\u201354."},{"key":"9321_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ejpb.2004.03.006","volume":"58","author":"ML Vueba","year":"2004","unstructured":"Vueba ML, Batista de Carvalho LAE, Veiga F, Sousa JJ, Pina ME. Influence of cellulose ether polymers on ketoprofen release from hydrophilic matrix tablets. Eur J Pharm Biopharm. 2004;58:51\u20139.","journal-title":"Eur J Pharm Biopharm"},{"key":"9321_CR24","first-page":"17","volume":"4","author":"T Higuchi","year":"1965","unstructured":"Higuchi T, Connors K. Phase solubility techniques. Adv Anal Chem Instru. 1965;4:17\u2013123.","journal-title":"Adv Anal Chem Instru"},{"key":"9321_CR25","first-page":"101","volume-title":"Cyclodextrin inclusion complexes. In Cyclodextrin Technology","author":"J Szejtli","year":"1988","unstructured":"Szejtli J. Cyclodextrin inclusion complexes. In Cyclodextrin Technology. Dordrecht: Kluwer Academic Publishers; 1988. p. 101\u20132."},{"key":"9321_CR26","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.3109\/03639049409038378","volume":"20","author":"D Peri","year":"1994","unstructured":"Peri D, Wyandt CM, Cleary RW, Hickal AH, Jones AB. Inclusion complexes of tolnaftate with \u03b2-Cyclodextrin and hydroxy-\u03b2-cyclodextrin. Drug Dev Ind Pharm. 1994;20:1401\u201310.","journal-title":"Drug Dev Ind Pharm"},{"key":"9321_CR27","first-page":"255","volume":"39","author":"JJT Labenderia","year":"1993","unstructured":"Labenderia JJT, Lopez ME, Penin LS, Jato JLV. Glibornuride-\u03b2-cyclodextrin inclusion complexes: preparation, structural characterization, and in vitro dissolution behavior. J Pharm Biopharm. 1993;39:255\u20139.","journal-title":"J Pharm Biopharm"},{"key":"9321_CR28","first-page":"1","volume":"1","author":"L Chengsheng","year":"2005","unstructured":"Chengsheng L, Chenguang L, Kashappa HD. Enhancement of dissolution rate of valdecoxib using solid dispersions with polyethylene glycol 4000. Drug Dev Ind Pharm. 2005;1:1\u201310.","journal-title":"Drug Dev Ind Pharm"},{"issue":"8","key":"9321_CR29","first-page":"231","volume":"57","author":"DW Bloch","year":"1982","unstructured":"Bloch DW, Elegakey MA, Speiser PP. Solid dispersions of chlorthalidone in urea. Pharm Acta Helv. 1982;57(8):231\u20135.","journal-title":"Pharm Acta Helv"},{"key":"9321_CR30","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1021\/js950534b","volume":"85","author":"T Loftsson","year":"1996","unstructured":"Loftsson T, Brewster EM. Pharmaceutical application of cyclodextrins. 1. drug solubilization and stabilization. J Pharm Sci. 1996;85:1017\u201325.","journal-title":"J Pharm Sci"},{"issue":"4","key":"9321_CR31","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1248\/cpb.26.1162","volume":"26","author":"K Uekama","year":"1978","unstructured":"Uekama K, Hirayama F, Otagiri M, Ikeda K. Inclusion complexation of cyclodextrin with some sulfonamides in aqueous solution. Chem Pharm Bull. 1978;26(4):1162\u20137.","journal-title":"Chem Pharm Bull"},{"key":"9321_CR32","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0378-5173(97)00233-0","volume":"157","author":"JR Moyano","year":"1997","unstructured":"Moyano JR, Arias-Blanco MJ, Gine\u2019s JM, Giordano F. Study of the complexation behaviour of gliclazide with partially methylated b-cyclodextrin in solution and solid state. Int J of Pharm. 1997;157:239\u201343.","journal-title":"Int J of Pharm"},{"key":"9321_CR33","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1021\/cr970014w","volume":"98","author":"AR Hedges","year":"1998","unstructured":"Hedges AR. Industrial applications of cyclodextrins. Chem Rev. 1998;98:2035\u201344.","journal-title":"Chem Rev"},{"key":"9321_CR34","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/jps.2600790524","volume":"79","author":"ATM Serajuddin","year":"1990","unstructured":"Serajuddin ATM, Sheen PC, Augustine MA. Improved dissolution of poorly water soluble drug from solid dispersions in polyethylene: polysorbate 80 mixture. J Pharm Sci. 1990;79:463\u20134.","journal-title":"J Pharm Sci"},{"key":"9321_CR35","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1081\/DDC-120003859","volume":"28","author":"M Barzegar-Jalali","year":"2002","unstructured":"Barzegar-Jalali M, Maleki N, Garjani A, Khandar AA, Haji-Hosseinloo M, Jabbari RC, et al. Enhancement of dissolution rate and anti-inflammatory effects of piroxicam using solvent deposition technique. Drug Dev Ind Pharm. 2002;28:681\u20136.","journal-title":"Drug Dev Ind Pharm"},{"key":"9321_CR36","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1081\/PDT-120000291","volume":"6","author":"L Tang","year":"2001","unstructured":"Tang L, Khan SU, Muhmmad NA. Evaluation and selection of bio-relevant dissolution media for a poorly water soluble new chemical entity. Pharm Dev Technol. 2001;6:531\u201340.","journal-title":"Pharm Dev Technol"},{"key":"9321_CR37","unstructured":"Aulton ME. Pharmaceutical technology. In: Pharmaceutics: The Science of Dosage Form Design. London: Churchill Livingstone. 1988; 600\u2013616."}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-009-9321-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12249-009-9321-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-009-9321-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-009-9321-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T23:48:07Z","timestamp":1559605687000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12249-009-9321-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,29]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["9321"],"URL":"https:\/\/doi.org\/10.1208\/s12249-009-9321-3","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,29]]},"article-number":"1301"}}